V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.5 USD 11.11% Market Closed
Market Cap: 69.6m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

Wall Street
Price Targets

VTGN Price Targets Summary
VistaGen Therapeutics Inc

Wall Street analysts forecast VTGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTGN is 12.24 USD with a low forecast of 12.12 USD and a high forecast of 12.6 USD.

Lowest
Price Target
12.12 USD
385% Upside
Average
Price Target
12.24 USD
390% Upside
Highest
Price Target
12.6 USD
404% Upside
VistaGen Therapeutics Inc Competitors:
Price Targets
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
28% Upside
PHM
Pharma Mar SA
2% Downside
LGND
Ligand Pharmaceuticals Inc
11% Upside
REGN
Regeneron Pharmaceuticals Inc
58% Upside
002007
Hualan Biological Engineering Inc
20% Upside
ELYM
Eliem Therapeutics Inc
230% Upside
BIIB
Biogen Inc
74% Upside
PRLD
Prelude Therapeutics Inc
324% Upside

Revenue
Forecast

Revenue Estimate
VistaGen Therapeutics Inc

The compound annual growth rate of VistaGen Therapeutics Inc's revenue for the next 3 years is 64%.

N/A
Past Growth
64%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-76%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VTGN's stock price target?
Price Target
12.24 USD

According to Wall Street analysts, the average 1-year price target for VTGN is 12.24 USD with a low forecast of 12.12 USD and a high forecast of 12.6 USD.

What is VistaGen Therapeutics Inc's Revenue forecast?
Projected CAGR
64%

The compound annual growth rate of VistaGen Therapeutics Inc's revenue for the next 3 years is 64%.

Back to Top